Mirum's Livmarli wins Phase 3 trial in biliary atresia
Mirum shares rose Monday after its drug LIVMARLI significantly reduced itch and bile acid levels in patients. Mirum is now seeking a third liver indication from the FDA.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Mirum Pharmaceuticals announced that its drug LIVMARLI succeeded in a Phase 3 trial in patients with biliary atresia. The trial showed significant reductions in itch and bile acid. Mirum's stock rose on Monday following the result.
Why it matters
The win positions Mirum to seek a third rare liver indication for Livmarli from the FDA, which it expects early next year.
Coverage
- Mirum on its way to 3rd rare liver indication for Livmarli (fiercepharma.com)
- Why Is Mirum Pharmaceuticals Stock Gaining Monday? (benzinga.com)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials